
DMPK
Viva biotech has built in vitro ADME and in vivo PK platforms for early DMPK screening, MS focused metabolite ID service, biomarker research, and Radio-isotope labeled DMPK studies. The DMPK team is headed by Dr. Shawn Cheng, a 13 year senior scientist at Abbott Laboratories and an expert in the area of biological screening, mass spectrometry, and its application in drug discovery. Dr. Cheng has dozens of first-authored or co-authored papers in Nature, JACS (8), and PNAS etc.
Viva DMPK services include:
In Vivo DMPK
Small and Large Animal PK
Routes of administration (PO, IV, IP, SC etc.) and sampling
Several different routes of administration for pain models
Tissue Distribution
Radioisotope labeled study – drugs/metabolites
LCMS based – drugs/metabolites and endogenous metabolites/biomarkers
Cancer tissue – drug and metabolite/biomarker concentration
In Vivo Drug Metabolism
Radioisotope labeled study
LCMS and NMR analysis
Biliary Excretion
Rats and dogs
In Vitro ADMET
Liver Microsomal Stability and Clearance
Human and animal
LCMS analysis
Plasma Protein Binding
Dialysis based
LCMS analysis
PAMPA Permeability
LCMS based
PGP efflux test available
Drug Metabolism
Phase I and II
Reactive metabolites
Structural identification – LCMS and NMR
Expertise -- In Vitro ADMET
CYP Inhibition
1A2, 2C9, 2D6, 3A4
CYP Induction
1A, 2B6, 3A4
Transporters
PGP inhibition/efflux
Amine transporters
Amino acid transporters
hERG Inhibition
Radioligand binding
Radio-Isotope Labeled DMPK Studies
Handles commonly used Isotopes (3H, 14C, 35S, 125I, 32P)
Capable of radio-labeling of cmpds, peptide/protein
Capable of in vivo PK/PD studies (including non human primate)
Binding assays
MS Expertise for Metabolite ID and Biomarker Research
Our facilities include:
5,000 sq ft in-house animal facility for mice, rats, rabbits, and dogs;
5,000 sq ft animal facility for isotope-labeled DMPK (SINAP);
API 3000 LCMS;
TOF-MS.


